FBIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Fortress Biotech Inc (FBIO) is not a strong buy for a beginner, long-term investor at this moment. While the company has a positive catalyst in the form of improved liquidity from the sale of its Rare Pediatric Disease Priority Review Voucher, the overall financial performance and technical indicators do not strongly support an immediate buy decision. The lack of significant trading trends, neutral sentiment from insiders and hedge funds, and no recent congress trading data further suggest a cautious approach.
The technical indicators show mixed signals. The MACD is positive but contracting, RSI is neutral at 54.057, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock price is currently below the pivot level of 3.675, indicating potential downward pressure. Key support levels are at 3.327 and 3.113, while resistance levels are at 4.023 and 4.237.
The sale of the Rare Pediatric Disease Priority Review Voucher for $205 million is a significant positive catalyst, improving liquidity and financial stability. This could support R&D efforts and enhance shareholder value.
The company's financial performance in Q3 2025 showed a significant decline in net income (-124.43% YoY) and EPS (-114.47% YoY), alongside a drop in gross margin (-3.99% YoY). These metrics indicate challenges in profitability despite revenue growth.
In Q3 2025, revenue increased by 20.52% YoY to $17.63 million, but net income dropped by 124.43% YoY to $3.675 million. EPS fell by 114.47% YoY to 0.11, and gross margin declined to 61.32%, down 3.99% YoY. This indicates growth in revenue but significant struggles with profitability.
No data available for recent analyst ratings or price target changes.
